Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Search

Total 87 results found. Search for [ Indian Pharmaceutical Alliance ]

Results 1 to 21 of 87
E Kumar Sharma
New Delhi, June 12, 2018
Indian pharma is on edge with an expected pharma pricing overhaul, but nothing is known yet on the shape of things to come.


BusinessToday.In
June 10, 2018
During the summit, India signed various agreements with the member countries including host nation China. Prime Minister Modi held nearly half a dozen bilateral meetings with leaders of other SCO countries.


PB Jayakumar
New Delhi, March 7, 2018
The Indian pharmaceutical industry, earlier reeling under the regulatory scanner of the USFDA, is learning from its mistakes.


PB Jayakumar
New Delhi, March 5, 2018
Out of the 192 inspections held by the US FDA in India in 2017, only eight were referred for Official Action indicated (OAI) or found out objectionable conditions at the audit site


E Kumar Sharma
New Delhi, February 1, 2018
The measures announced in the budget could trigger a rise in demand for medicines but those within the Indian pharma feel this alone may not help.


E Kumar Sharma
New Delhi, January 12, 2018
Many companies, with some leading players, are already coping with challenges around price erosion in generics, erosion of base business resulting from new competition and buyer consolidation in their biggest global market, the US.


PTI
December 27, 2017



P.B. Jayakumar
New Delhi, December 11, 2017
Margin erosion and regulatory hurdles are hitting Indian pharma companies hard in their biggest market.


Anilesh S. Mahajan
New Delhi, December 11, 2017
India clamps down on Chinese imports citing the one-sided nature of the engagement. But the process of weaning away industry from cheaper imports will not be easy.


E. kumar sharma
New Delhi, December 11, 2017
Indian pharma companies are facing strong headwinds, but they are also exploring every new opportunity to ensure a quick recovery.


E. Kumar Sharma
New Delhi, November 25, 2017
Pharma stocks continue to underperform as policy uncertainty adds to the toll taken by USFDA and market challenges.


E Kumar Sharma
November 21, 2017
The US Food and Drug Administration (USFDA) seems to have sent out a strong message to pharmaceutical companies in India on the need to adhere to a quality culture and on matters relating to data integrity.


E Kumar Sharma
New Delhi, November 12, 2017
Every business has the right to adopt legitimate practises to protect their own interest. Right? But a recent article argues that going beyond the patent act, which permits research and development during the life of a patent, some innovator drug companies are busy trying to block this.


E Kumar Sharma
New Delhi, November 6, 2017
Why should there be the Goods and Services Tax on materials that cannot be sold? That is the question, the Indian pharmaceutical industry, is hoping will get addressed in the final tweaking of the GST provisions.


E Kumar Sharma
New Delhi, October 24, 2017
On October 20th the ministry of chemicals and fertilizers issued a press note in what seems an attempt to allay industry fears on the issue of price controls.


E Kumar Sharma
New Delhi, August 28, 2017
The most striking thing about the policy draft is, that it has good policy goals but gives little thought on the road map and challenges in meeting them.


E Kumar Sharma
New Delhi, August 21, 2017
Certain pharma industry leaders point out that the draft of new pharmaceutical policy has been written in an amateurish manner.


E Kumar Sharma
New Delhi, August 17, 2017
On August 3rd, the largest generic company operating in the US, Teva Pharmaceutical Industries (Teva in quickspeak) put out results that arguably jolted the world of global generic medicines.


E Kumar Sharma
May 16, 2017
The difference this time is that now there is a Trade Facilitation and Trade Enforcement Act (TFTEA) and according to this, the US Congress can ask the USTR what specific actions they have proposed or taken against a country, which is on the priority watch list for more than a year, and India falls under that category.


By Joe C. Mathew
Delhi, March 20, 2017
In spite of favourable court verdicts, top pharmaceutical companies are losing enthusiasm for fixed dose combination medicines.


PAGES 1 OF 5  12345